Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1128916

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with estrogen receptor positive breast cancer receive endocrine therapy, however half fail to respond and relapse. Endocrine resistant breast cancer currently represents the most significant challenge to breast cancer treatment. We suggest that three-dimensional epigenetic remodelling is an underlying mechanism that determines endocrine sensitivity that we will exploit as a novel therapeutic strategy to effectively treat patents with recurrent disease.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $828,560.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Epigenetics (incl. Genome Methylation and Epigenomics)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

DNA methylation | breast cancer | chromatin structure | drug resistance | gene expression

Related Links